epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Cobenfy
    xanomeline/ trospium
  • remove Liqrev
    sildenafil
  • remove Tadliq
    tadalafil
  • remove Tyvaso DPI
    treprostinil inhaled

multicheck MultiCheck Results - 4 Interactions

Smiley face Smiley face

Avoid/Use Alternative

Smiley face Smiley face Liqrev (sildenafil) + Tadliq (tadalafil)

Avoid/Use Alternative


sildenafil + tadalafil

avoid combo: combo may incr. risk of hypotension, auditory, vestibular, other adverse effects (additive effects, duplicate therapy)

Monitor/Modify Tx

Smiley face Smiley face Cobenfy (xanomeline/ trospium) + Tadliq (tadalafil)

Monitor/Modify Tx


xanomeline + tadalafil

monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (GI metabolism possibly inhibited)

Smiley face Smiley face Liqrev (sildenafil) + Tyvaso DPI (treprostinil inhaled)

Monitor/Modify Tx


sildenafil + treprostinil

monitor BP: combo may incr. risk of severe hypotension, including syncope (additive effects)

Smiley face Smiley face Tadliq (tadalafil) + Tyvaso DPI (treprostinil inhaled)

Monitor/Modify Tx


tadalafil + treprostinil

monitor BP: combo may incr. risk of severe hypotension, including syncope (additive effects)

Additional Considerations

Smiley face Smiley face trospium in Cobenfy

avoid combo with beverages or products containing ethanol within 2h of trospium extended-release (ER) capsules administration; combo may incr. trospium release rate, levels, risk of adverse effects, decr. duration of efficacy

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information